Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
FDA Grants Priority Review to Frontline Keytruda Combination in Metastatic NSCLC
July 2nd 2018The Food and Drug Administration (FDA) granted a priority review to Keytruda (pembrolizumab) in combination with chemotherapy as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 expression, according to Merck, the manufacturer of the anti-PD-1 agent.
Read More
Insurance Disparities Among Medicaid Patients with NSCLC Leads to Worse Survival
June 21st 2018According to findings from the ASCO Annual Meeting, insurance disparities still exist, and may even contribute to cancer-specific and comorbidity-associated mortalities in patients with early-stage non-small cell lung cancer.
Read More
Genetic Predisposition Affects Treatment, Surveillance of Children with Medulloblastoma
June 18th 2018Researchers identified six gene variations that play an important role in the treatment and surveillance of children with medulloblastoma, for which they developed screening and counseling recommendations.
Read More
Testing Only the 'Tip of the Iceberg' for Common Hereditary Condition in MSI-H Tumors
June 14th 2018Lynch syndrome – a hereditary condition that increases a person’s risk for developing several types of cancer – is common among people with microsatellite instability-high (MSI-H) tumors, linking it to several new cancer types, according to large genomic study results presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Read More
Frontline Keytruda Effective in NSCLC Subgroup, But More Work Is Needed
June 13th 2018In the Keynote-042 trial, researchers found a four- to eight-month overall survival benefit among patients with non-small cell lung cancer (NSCLC), which was correlated with higher levels of PD-L1 expression, however, further study is warranted.
Read More
FDA Grants Priority Review to GARDASIL 9 for Expanded Age Indication
June 13th 2018The application is seeking approval for GARDASIL 9 to be used in women and men aged 27 to 45 years for the prevention of certain cancers and diseases caused by the nine human papillomavirus (HPV) types covered by the vaccine.
Read More
Venclexta Combination Receives Full FDA Approval for CLL, With or Without 17p deletion
June 8th 2018The Food and Drug Administration (FDA) approved Venclexta (venetoclax) in combination with Rituxan (rituximab) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without the genetic mutation 17p deletion, who have received at least one prior therapy.
Read More
FDA Approves Leukine to Treat Blood-Related Acute Radiation Syndrome
June 6th 2018The Food and Drug Administration (FDA) approved Leukine (sargramostim) for the treatment of adult and pediatric patients who are exposed to myelosuppressive doses of radiation that results in a hematopoietic subsyndrome of acute radiation syndrome.
Read More
FDA Approves First Biosimilar to Reduce Risk of Infection During Cancer Treatment
June 5th 2018The Food and Drug Administration (FDA) approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to reduce the risk for febrile neutropenia in patients treated with chemotherapy in certain types of cancer.
Read More
Immunotherapy Combination Shows Promise, Side Effects Ensue in Colorectal Cancer Subgroup
May 25th 2018Despite improved outcomes, the researchers also found that side effects with checkpoint inhibition often affected the dermatologic, gastrointestinal, pulmonary, renal, endocrine and hepatic systems in patients.
Read More
Navigating the Waves of Cancer Treatment
May 17th 2018In this week’s episode of CURE Talks Cancer, we spoke with Matt Lashey, creator and CEO of the chemoWave app, which is designed to manage cancer symptoms and conditions by keeping track of a patient’s overall well-being to understand how their experiences may be related to feeling better or worse during treatment.
Read More